Virginia Oncology Associates

Recent papers from Virginia Oncology Associates

1. Bridging the gap in cell and gene therapy: addressing operational and financial barriers to achieve sustainable access.2026
2. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialThe Lancet · 2016
3. Baseline Lymphopenia Predicts Survival in ICI-Naïve Solid Tumor Patients Receiving Immune Checkpoint Inhibitors: A Propensity-Matched Real-World Pan-Cancer AnalysisCancers · 2026
4. Directly comparing randomized and real-world controls in adjuvant breast cancerJournal of Comparative Effectiveness Research · 2026
5. A phase 3 study of olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia: POLARIS-2 trial in progress.Journal of Clinical Oncology · 2026
6. Progress report of a phase 2 study of BPM31510 (a lipid nano dispersion of oxidized CoQ10) with vitamin K in combination with standard of care (SOC) RT and TMZ in glioblastoma multiforme (GBM) patients without prior therapy.Journal of Clinical Oncology · 2026
7. Comparative analysis of hereditary cancer genetic testing programs in India and the US: Identifying disparities and guiding global program development.Journal of Clinical Oncology · 2026
8. Real-world clinical outcomes of neoadjuvant pembrolizumab among patients with early-stage triple-negative breast cancer (esTNBC) in a US community oncology setting.Journal of Clinical Oncology · 2026
9. KITE-753: A phase 2 study of an autologous anti-CD19/CD20 CAR T-cell therapy in CAR-naive patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).Journal of Clinical Oncology · 2026
10. Real-world (rw) study of the treatment journey following antibody-drug conjugate (ADC) initiation and overall survival (OS) in breast cancer (BC) in a US community setting.Journal of Clinical Oncology · 2026
11. Achieving epidemiologically representative enrollment and social determinants of health in the phase III evERA Breast Cancer study (NCT05306340).Journal of Clinical Oncology · 2026
12. Optec/Optal: A phase 2 study to evaluate outpatient (OP), step-up administration of teclistamab (Tec) or talquetamab (Tal) with prophylactic tocilizumab (prophyToci) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).Journal of Clinical Oncology · 2026
13. Long-term B-cell depletion with rituximab in relapsing, refractory and severe lupus nephritis: a retrospective case seriesClinical Kidney Journal · 2026
14. Biomarker Testing Rates and Patterns in Patients With Metastatic Non–Small Cell Lung Cancer: A Prospective, Observational Study in Community PracticesJCO Precision Oncology · 2026
15. Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trialThe Lancet · 2026
16. Outpatient Administration of Bispecific Therapies in a Community Oncology SettingTransplantation and Cellular Therapy · 2026
17. Real-World Barriers and Opportunities for Cell and Gene Therapy (CGT): An Analysis of US Hematologist and Oncologist Insights on Readiness and AccessTransplantation and Cellular Therapy · 2026
18. PS5-09-23: A Phase 2 study of zelenectide pevedotin, a Bicycle Drug Conjugate, in patients with NECTIN4 amplified advanced breast cancer (Duravelo-3)Clinical Cancer Research · 2026
19. PS5-10-27: Integrating Virtual Collaborative Care Behavioral Health in Breast Cancer Care: Improving Outcomes in Mental Health, Adherence, and Racial EquityClinical Cancer Research · 2026
20. Abstract PS5-12-21: Herthena-breast03: a phase 2, randomized, open-label study evaluating neoadjuvant patritumab deruxtecan (HER3-DXd) + pembrolizumab before or after pembrolizumab + chemotherapy for early-stage TNBC or HR-low+/HER2− breast cancerClinical Cancer Research · 2026